Alexander Warkentin

Alexander Warkentin is a highly experienced scientist specializing in chemistry and medicinal chemistry, currently serving as Principal Scientist at PTC Therapeutics, Inc. since October 2019. Previous roles include significant positions at BioElectron Technology Corporation and a post-doctoral scholarship at the University of California, San Francisco, where notable research on the FLT3 receptor was conducted. A graduate of Princeton University with a PhD in Organic Chemistry, Warkentin has made substantial contributions to the field through innovative discoveries in organocatalytic methods and medicinal chemistry. Early career experiences include an internship at Wyeth Neurodegenerative Research and research assistance at the University of California, Berkeley.